- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 219-233 of
249 results
2136 Exhibit: McElroy et al, Pharmacologic Agents for the Treatment of AcuteBipol...
Document
IPR2020-01053, No. 2136 Exhibit - McElroy et al, Pharmacologic Agents for the Treatment of AcuteBipolar Mania (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2067 Exhibit: DiMasi et al The price of innovation new estimates of drugdevelopmen...
Document
IPR2020-01053, No. 2067 Exhibit - DiMasi et al The price of innovation new estimates of drugdevelopment costs (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2070 Exhibit: Latuda Product Monograph
Document
IPR2020-01053, No. 2070 Exhibit - Latuda Product Monograph (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2056 Exhibit: Stimmel at al, Ziprasidone An Atypical Antipsychotic Drug for theTrea...
Document
IPR2020-01053, No. 2056 Exhibit - Stimmel at al, Ziprasidone An Atypical Antipsychotic Drug for theTreatment of Schizophrenia (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2091 Exhibit: Comparison of Atypical Antipsychotics
Document
IPR2020-01053, No. 2091 Exhibit - Comparison of Atypical Antipsychotics (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2047 Exhibit: Nashed et al, Olanzapine Induced Weight Gain in Patients withBipola...
Document
IPR2020-01053, No. 2047 Exhibit - Nashed et al, Olanzapine Induced Weight Gain in Patients withBipolar I Disorder A Meta Analysis (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2142 Exhibit: News Release Sunovion Pharmaceuticals Inc Announces FDAApprov...
Document
IPR2020-01053, No. 2142 Exhibit - News Release Sunovion Pharmaceuticals Inc Announces FDAApproval of Latuda lurasidone HCl as Monotherapy andAdjunctive Therapy in Adult Patients with...
|
|
Cite Document
2071 Exhibit: O���Day et al, Long term cost effectiveness of atypical antipsychoticsi...
Document
IPR2020-01053, No. 2071 Exhibit - O���Day et al, Long term cost effectiveness of atypical antipsychoticsin the treatment of adults with schizophrenia in the US (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2066 Exhibit: Reiffen et al, Generic Drug Industry Dynamics
Document
IPR2020-01053, No. 2066 Exhibit - Reiffen et al, Generic Drug Industry Dynamics (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2140 Exhibit: M��ller, J Clin Psych
Document
IPR2020-01053, No. 2140 Exhibit - M��ller, J Clin Psych (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2052 Exhibit: Hoyberg et al, Risperidone versus perphenazine in the treatment ofch...
Document
IPR2020-01053, No. 2052 Exhibit - Hoyberg et al, Risperidone versus perphenazine in the treatment ofchronic schizophrenic patients with acute exacerbations (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2084 Exhibit: Ng Mak et al, Patient Preferences for Important Attributes of BipolarD...
Document
IPR2020-01053, No. 2084 Exhibit - Ng Mak et al, Patient Preferences for Important Attributes of BipolarDepression Treatments (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2045 Exhibit: Shayegan et al, Atypical Antipsychotics Matching Receptor Profile to...
Document
IPR2020-01053, No. 2045 Exhibit - Shayegan et al, Atypical Antipsychotics Matching Receptor Profile to Individual Patients Clinical Profile (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2044 Exhibit: Franklin, Lurasidone for the treatment of bipolar depression an evide...
Document
IPR2020-01053, No. 2044 Exhibit - Franklin, Lurasidone for the treatment of bipolar depression an evidence based review (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2054 Exhibit: Sachs et al, Efficacy and Safety of Adjunctive Oral Ziprasidone forAc...
Document
IPR2020-01053, No. 2054 Exhibit - Sachs et al, Efficacy and Safety of Adjunctive Oral Ziprasidone forAcute Treatment of Depression in Patients With Bipolar I Disorder (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
